Fluorouracil
- Generic Name
- Fluorouracil
- Brand Names
- Actikerall, Carac, Efudex, Fluoroplex, Tolak
- Drug Type
- Small Molecule
- Chemical Formula
- C4H3FN2O2
- CAS Number
- 51-21-8
- Unique Ingredient Identifier
- U3P01618RT
- Background
A pyrimidine analog that is an antineoplastic antimetabolite. It interferes with DNA synthesis by blocking the thymidylate synthetase conversion of deoxyuridylic acid to thymidylic acid.
- Indication
For the topical treatment of multiple actinic or solar keratoses. In the 5% strength it is also useful in the treatment of superficial basal cell carcinomas when conventional methods are impractical, such as with multiple lesions or difficult treatment sites. Fluorouracil injection is indicated in the palliative management of some types of cancer, including colon, esophageal, gastric, rectum, breast, biliary tract, stomach, head and neck, cervical, pancreas, renal cell, and carcinoid.
- Associated Conditions
- Actinic Keratosis (AK), Breast Cancer, Colon Cancer, Gastric Cancer, Pancreatic Cancer, Rectal Cancer, Superficial Basal Cell Carcinoma, Verruca (Warts), Hyperkeratotic actinic keratosis
- Associated Therapies
- -
Irinotecan/Oxaliplatin/5-Fluorouracil/Leucovorin/Cetuximab As First Line Treatment In Colorectal Cancer
- Conditions
- Metastatic Colorectal Cancer
- Interventions
- First Posted Date
- 2008-06-03
- Last Posted Date
- 2015-09-28
- Lead Sponsor
- University Hospital of Crete
- Target Recruit Count
- 30
- Registration Number
- NCT00689624
- Locations
- 🇬🇷
University Hospital of Crete, Heraklion, Greece
Cetuximab and Combination Chemotherapy in Patients With Stage III-IV Resectable Oropharynx Cancer
- Conditions
- Head and Neck Cancer
- Interventions
- First Posted Date
- 2008-04-23
- Last Posted Date
- 2021-06-25
- Lead Sponsor
- GERCOR - Multidisciplinary Oncology Cooperative Group
- Target Recruit Count
- 42
- Registration Number
- NCT00665392
- Locations
- 🇫🇷
Hopital Bichat - Claude Bernard, Paris, France
🇫🇷Hôpital Simone Veil, Montmorency, France
🇫🇷Hôpital Privé St Joseph, Paris, France
Chemotherapy and Radiation Following Pancreatic Surgery
- Conditions
- Pancreatic Cancer
- Interventions
- Procedure: Pancreatic SurgeryRadiation: Radiation therapyDrug: CisplatinDrug: 5-FUDrug: Alpha-interferonDrug: Gemcitabine
- First Posted Date
- 2008-04-17
- Last Posted Date
- 2013-04-23
- Lead Sponsor
- Washington University School of Medicine
- Target Recruit Count
- 53
- Registration Number
- NCT00660270
- Locations
- 🇺🇸
Washington University School of Medicine, St. Louis, Missouri, United States
Irinotecan, Fluorouracil, and Leucovorin in Treating Patients With Advanced Gastrointestinal Cancer
- Conditions
- Extrahepatic Bile Duct CancerAnal CancerCarcinoma of the AppendixGastric CancerGastrointestinal Carcinoid TumorEsophageal CancerGallbladder CancerGastrointestinal Stromal TumorLiver CancerPancreatic Cancer
- First Posted Date
- 2008-04-07
- Last Posted Date
- 2017-05-25
- Lead Sponsor
- Mayo Clinic
- Target Recruit Count
- 7
- Registration Number
- NCT00654160
- Locations
- 🇺🇸
Mayo Clinic, Rochester, Minnesota, United States
Fluorouracil and Oxaliplatin With or Without Panitumumab In Treating Patients With High-Risk Colon Cancer That Can Be Removed by Surgery
- Conditions
- Colorectal Cancer
- Interventions
- First Posted Date
- 2008-03-31
- Last Posted Date
- 2019-05-17
- Lead Sponsor
- University of Birmingham
- Target Recruit Count
- 1053
- Registration Number
- NCT00647530
- Locations
- 🇬🇧
Huddersfield Royal Infirmary, Huddersfield, West Yorks, England, United Kingdom
🇬🇧Derriford Hospital, Plymouth, England, United Kingdom
🇬🇧Queen Elizabeth Hospital, Gateshead, England, United Kingdom
Cetuximab, Combination Chemotherapy, and Radiation Therapy in Treating Patients With Newly Diagnosed Stage III or Stage IV Head and Neck Cancer That Cannot Be Removed By Surgery
- Conditions
- Head and Neck Cancer
- First Posted Date
- 2008-03-28
- Last Posted Date
- 2018-07-09
- Lead Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
- Target Recruit Count
- 47
- Registration Number
- NCT00646659
- Locations
- 🇧🇪
Universitair Ziekenhuis Antwerpen, Edegem, Belgium
A Study of Avastin (Bevacizumab) in Combination With Chemotherapy in Chinese Patients With Metastatic Colorectal Cancer.
- Conditions
- Colorectal Cancer
- Interventions
- First Posted Date
- 2008-03-25
- Last Posted Date
- 2022-12-22
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 214
- Registration Number
- NCT00642577
Erlotinib and Chemotherapy for 2nd Line Treatment (Tx) of Metastatic Colorectal Cancer (mCRC)
- Conditions
- Metastatic Colorectal Cancer
- Interventions
- First Posted Date
- 2008-03-25
- Last Posted Date
- 2014-09-26
- Lead Sponsor
- OHSU Knight Cancer Institute
- Target Recruit Count
- 16
- Registration Number
- NCT00642746
- Locations
- 🇺🇸
Oregon Health & Science University, Portland, Oregon, United States
Combination Chemotherapy and Cetuximab as First-Line Therapy in Treating Patients With Advanced and/or Metastatic Colorectal Cancer
- Conditions
- Colorectal Cancer
- Interventions
- Biological: cetuximabDrug: capecitabineDrug: fluorouracilDrug: leucovorin calciumDrug: oxaliplatinOther: immunohistochemistry staining methodOther: laboratory biomarker analysis
- First Posted Date
- 2008-03-20
- Last Posted Date
- 2021-09-22
- Lead Sponsor
- Cheryl Pugh
- Target Recruit Count
- 169
- Registration Number
- NCT00640081
- Locations
- 🇬🇧
Weston Park, Sheffield, United Kingdom
🇬🇧Darent Valley Hospital, Dartford, United Kingdom
🇬🇧Guys and St Thomas' hospitals, London, United Kingdom
Endoscopic Ultrasound in Diagnosing Cancer in Patients With Localized Stomach Cancer or Esophageal Cancer
- Conditions
- Esophageal CancerGastric Cancer
- First Posted Date
- 2008-03-06
- Last Posted Date
- 2013-08-07
- Lead Sponsor
- North Wales Organisation for Randomised Trials in Health
- Target Recruit Count
- 700
- Registration Number
- NCT00629863
- Locations
- 🇬🇧
Royal Infirmary - Castle, Glasgow, Scotland, United Kingdom
🇬🇧Gloucestershire Royal Hospital, Gloucester, England, United Kingdom
🇬🇧North Tyneside Hospital, North Shields, England, United Kingdom
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.